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ABSTRACT Dysfunctional tau accumulation is a major
contributing factor in tauopathies, and the heat-shock
protein 70 (Hsp70) seems to play an important role in this
accumulation. Several reports suggest that Hsp70 proteins
can cause tau degradation to be accelerated or slowed, but
how these opposing activities are controlled is unclear.
Here we demonstrate that highly homologous variants in
the Hsp70 family can have opposing effects on tau
clearance kinetics. When overexpressed in a tetracycline
(Tet)-based protein chase model, constitutive heat shock
cognate 70 (Hsc70) and inducible Hsp72 slowed or accel-
erated tau clearance, respectively. Tau synergized with
Hsc70, but not Hsp72, to promote microtubule assembly
at nearly twice the rate of either Hsp70 homologue in
reconstituted, ATP-regenerating Xenopus extracts supple-
mented with rhodamine-labeled tubulin and human re-
combinant Hsp72 and Hsc70. Nuclear magnetic reso-
nance spectroscopy with human recombinant protein
revealed that Hsp72 had greater affinity for tau than
Hsc70 (I/I0 ratio difference of 0.3), but Hsc70 was 30
times more abundant than Hsp72 in human and mouse
brain tissue. This indicates that the predominant Hsp70
variant in the brain is Hsc70, suggesting that the brain
environment primarily supports slower tau clearance.
Despite its capacity to clear tau, Hsp72 was not induced in
the Alzheimer’s disease brain, suggesting a mechanism for
age-associated onset of the disease. Through the use of
chimeras that blended the domains of Hsp72 and Hsc70,
we determined that the reason for these differences
between Hsc70 and Hsp72 with regard to tau clearance
kinetics lies within their C-terminal domains, which are
essential for their interactions with substrates and cochap-
erones. Hsp72 but not Hsc70 in the presence of tau was
able to recruit the cochaperone ubiquitin ligase CHIP,
which is known to facilitate the ubiquitination of tau,
describing a possible mechanism of how the C-termini of
these homologous Hsp70 variants can differentially regu-
late tau triage. Thus, efforts to promote Hsp72 expression
and inhibit Hsc70 could be therapeutically relevant for
tauopathies.—Jinwal, U. K., Akoury, E., Abisambra, J. F.,
O’Leary, J. C., III, Thompson, A. D., Blair, L. J., Jin, Y.,
Bacon, J., Nordhues, B. A., Cockman, M., Zhang, J., Li, P.,
Zhang, B., Borysov, S., Uversky, V. N., Biernat, J., Man-
delkow, E., Gestwicki, J. E., Zweckstetter, M., Dickey, C. A.
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The microtubule-associated protein tau, when dis-
engaged from microtubules, becomes deleterious in
tauopathies (1–4). Part of this pathogenesis involves
structural changes that promote its aggregation. Chap-
erone machinery, and in particular members of the
heat-shock protein 70 (Hsp70) family, are engaged with
tau during these pathogenic events, and these proteins
dramatically affect tau stability and function at this
critical juncture (5–7). In mammalian systems, there
are 13 homologous Hsp70 genes, including the pri-
mary cytosolic variants heat-shock cognate 70 (Hsc70;
HSPA8) and Hsp72 (HSPA1A). Though these two vari-
ants share nearly 80% sequence identity, some func-
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tional differences have been reported (8, 9). Hsc70 is
constitutively expressed (10), whereas Hsp72 is ex-
pressed in response to stress (11). Moreover, the C
termini of these chaperones, known to interact with key
cochaperone effectors containing a tetratricopeptide
(TPR) repeat motif, is where their sequences differ the
most (12). Despite these observations, the term Hsp70
is often used to generically refer to both Hsc70 and
Hsp72.
We and others have shown that the collective Hsp70
chaperone network, and in particular Hsp72 and
Hsc70, influences tau conformation, degradation, and
aggregation kinetics. But how these fates are chosen for
tau has been challenging to define. For example, some
studies strongly suggest that overexpression of an un-
specified Hsp70 variant can facilitate tau clearance (5),
whereas others suggest that both Hsp72 and Hsc70
restore tau’s binding to microtubules (1, 7). Though
differences in the cellular environment, such as stress
(12) and client abundance (13) may contribute to this
discrepancy, it has yet to be definitively shown how
these different fates for tau are chosen by the Hsp70
machinery. We show here that tau fate is critically
linked to both Hsc70 and Hsp72.
MATERIALS AND METHODS
Materials
Hsc70 and Hsp72 antibodies were purchased from Stressgen
(Famingdale, NY, USA), and specificity was validated as
described previously (8). Total tau H150 antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Actin and GAPDH antibodies were purchased from
Sigma (St. Louis, MO, USA) and Biodesign International
(Memphis, TN, USA), respectively. Myc and Flag antibodies
were obtained from Roche (Indianapolis, IN, USA) and
Sigma, respectively. Carboxyl terminus of Hsc70-interacting
protein (CHIP) antibody was provided by Cell Signaling
(Danvers, MA, USA). Phosphatase inhibitor cocktails (1 and
3), albendazole, and celastrol were purchased from Sigma.
Cell lysis buffer M-PER was purchased from Fisher Scientific
(Pittsburgh, PA, USA). Secondary antibodies horseradish
peroxidase linked were purchased from Southern Biotech
(Birmingham, AL, USA). Lipofectamine 2000 and secondary
antibodies conjugated to flourophore were purchased from
Invitrogen (Grand Island, NY, USA). Plasmids for wild-type
human Hsc70, Hsp72, and chimera were generated in the
pCMV6 vector (Origene, Rockville, MD, USA), which was
then engineered to contain an N-terminal Flag tag. Mutant
constructs were generated using the Site directed mutagene-
sis kit from Stratagene (Santa Clara, CA, USA). All other
clones were in pCDNA3.1 plasmid. Human brain tissue was
provided from the University of California at Irvine Alzhei-
mer’s Disease Research Center (UCI-ADRC) Institute for
Memory Impairments and Neurological Disorders (MIND;
Irvine, CA, USA).
Cell culture, immunoblotting, dot blot, immunostaining,
and immunoprecipitation
Human neuroblastoma IMR-32, human embryonic kidney
(HEK), and HeLa cells were maintained in OptiMEM me-
dium supplemented with 10% heat-inactivated fetal bovine
serum (FBS) and 1% penicillin/streptomycin antibiotic solu-
tion. All the transfections, immunoblotting, and immunopre-
cipitation experiments were performed as described previ-
ously (14). Dot blots were performed using the Whatman
Minifold I apparatus on nitrocellulose (Whatman, Piscataway,
NJ, USA). All values were normalized to Ponceau S. Recom-
binant Hsp72 and Hsc70 were applied at indicated molar
concentrations in PBS. Lysates from human Alzheimer’s
disease (AD) brain tissue and control brain tissue were
spotted at 20 g total protein. Quantification of Western blot
and dot blot data was performed using replicate values from
ScionImage (Scion Corp., Frederick, MD, USA) or ImageJ
(U.S. National Insitutes of Health, Bethesda, MD, USA)
densitometric software suites. Dot blot calculations were
performed using a semilog linear regression analysis. Immu-
nostaining of mouse brain tissue was performed as described
previously (15, 16).
Tetracycline (Tet)-based protein chase HEK cell model
Inducible HEK cell line was generated by the insertion of
human wild-type tau 4R0N DNA into a pCDNA 4/TO plasmid
vector carrying Zeocin selection (Invitrogen). The tau/TO
plasmid construct was transfected into the Tetracycline-Reg-
ulated Expression (T-Rex; Invitrogen) HEK cell lines stably
expressing Tet repressor under the selection of blasticidin.
After 24 h of DNA transfection, Zeocin (400 g/ml) and
blasticidin (5 g/ml) were added to the medum (DMEM
containing 10% FBS, 2 mM L-glutamine, and 1% Pen-Strep).
Every 3-4 d medium was replaced with fresh medium contain-
ing Zeocin and blasticidin. After 3 wk, double-stable cell
colonies were picked up and transferred into 6-well plates.
These colonies were induced by Tet (1 g/ml) and tested for
tau expression by Western blot. Tau-expressing double-stable
HEK cells were maintained under the selection of Zeocin and
blasticidin and used for the experimentation. Following trans-
fection with Hsp72 or Hsc70 clones, Tet-containing medium
was removed and replaced with normal medium. Tau levels
were reduced over time to near basal levels.
Live-cell imaging
HEK-293 cells were plated onto a 6-well plate and maintained
in DMEM plus 10% FBS and 1% of 200 mM l-glutamine.
Plasmid transfections were done utilizing Lipofectamine 2000
(Invitrogen). HEK 293 cells were transfected with 2 g of
Hsc70 DNA, 1 g of tubulin-green fluorescent protein (GFP)
DNA, and 1 g of tau-red fluorescent protein (RFP) DNA.
The cells were incubated overnight with the Lipofectamine/
plasmid mixture in Opti-MEM medium, and replaced with
fresh complete medium for an additional 36 h. An Olympus
FV1000 MPE multiphoton laser scanning microscope (Olym-
pus, Tokyo, Japan) was used to capture images. Image analysis
was completed with the Olympus FV10-ASW software, and
significance was assessed by Pearson’s correlation coefficient.
Cells were then lysed and analyzed by Western blot to confirm
overexpression of Hsp72 and Hsc70.
Recombinant protein production
The coding regions for WT 4R0N tau, Hsp72, and Hsc70 were
separately PCR amplified and subcloned into pET28A vectors
with N-terminal His6 tags. Resulting plasmids were trans-
formed into E. coli OneShot BL21 Star (DE3) cells (Invitro-
gen), and 10 ml starter cultures were grown overnight in
Luria-Bertani (LB) medium with 30 g/ml kanamycin. Cells
were then inoculated into 1.0 L LB medium, grown at 37°C to
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A600  0.7–0.8, and induced with 1 mM isopropyl -d-1-
thiogalactopyranoside. After 3 h of continued growth at 37°C,
cells were harvested by centrifugation and resuspended in
lysis buffer [500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole,
1 protease inhibitor cocktail III (Calbiochem, Billerica, MA,
USA), and 1 mM PMSF, pH 8.0]. The cells were then lysed by
sonication and centrifuged (18,200 g, 30 min, 4°C), and
supernatant was loaded onto 5 ml of charged Ni-NTA agarose
beads (Qiagen, Valencia, CA, USA). Protein was eluted in lysis
buffer containing 250 mM imidazole. Eluent was concen-
trated to 2 ml and loaded onto a HiLoad 16/60 Superdex 200
pg size-exclusion column. Purified fractions were dialyzed in
2 steps into 10 mM phosphate buffer (pH 7.5), and concen-
trations were determined by BCA.
In vitro microtubule assembly assay
These assays were performed as described previously (1, 14).
Briefly, S-phase Xenopus egg extracts were prepared according
to a standard protocol (17) and supplemented with 5%
DMSO to stimulate microtubule polymerization, as described
previously (18). Purified recombinant wild-type tau, Hsp72,
and Hsc70 proteins were added at the final concentrations of
40, 80, and 80 ng/l. The extracts were incubated 30 min at
room temperature, and obtained microtubule structures were
visualized by fluorescence of incorporated rhodamine-la-
beled tubulin.
Nuclear magnetic resonance (NMR)
15N-labeled human tau protein was expressed and purified as
described previously (19). NMR experiments were recorded
at 5°C on a Bruker Avance 800 MHz spectrometer (Bruker
Corp., Billerica, MA, USA) equipped with a cryogenic probe.
NMR samples contained 50 M 15N single-labeled tau protein
in 50 mM phosphate buffer and 10 mM NaCl (pH 6.8), 1 mM
DTT, and 10% (v/v) D2O. Unlabeled Hsp72 and Hsc70
samples were prepared in the same buffer. Two-dimensional
1H–15N heteronuclear single-quantum coherence (HSQC)
spectra were acquired using 600 complex points and 128
scans/increment with spectral widths of 8012 and 1944 Hz in
the 1H and 15N dimensions, respectively. Spectra were pro-
cessed with NMRPipe (20) and analyzed using CcpNMR
Analysis (21). NMR intensity ratio plots were reported with a
3-residues averaging window.
Immunostaining
Mouse brains were processed for immunohistochemical anal-
ysis as described previously (16, 22). Briefly, mouse brain
sections were immersed in 3% H2O2 solution for 15 min at
room temperature. After washing with PBS, sections were
permeabilized by immersing in the 4% donkey serum block-
ing buffer (supplemented with 1.83% lysine and 2% Triton
X-100) for 30 min at room temperature. Sections were treated
with anti-HSC70 (1:20000) and anti-Hsp72 (1:300) primary
antibodies overnight at 4°C. After washing with PBS, sections
were incubated with biotinylated anti-rat (1:1000) and anti-
mouse (1:3000) secondary antibodies (Southern Biotech) for
2 h and then with streptavidin-peroxidase. The peroxidase
reactions consisted of 1.4 mM diaminobenzidine with 0.03%
hydrogen peroxide in PBS for 5 min. Finally, stained sections
were mounted on glass slides, dehydrated, cleaned using
histoclean, and coverslipped. Imaging was performed with
the Zeiss Mirax slide-scanning microscope (Carl Zeiss,
Oberkochen, Germany).
Fluorescent polarization (FP) assay
FP assays were carried out essentially as described previously
(23). The peptide FITC-HLA (RENLRIARLY) was synthesized
on Wang resin using microwave-assisted DIC/HOBt solid-
phase peptide synthesis. It was capped with 2 -alanine
residues and labeled on resin via the N terminus with
fluorescein-5-isothiocyanate (AnaSpec, Fremont, CA, USA).
The final product was obtained in 90% purity. FP assays
were carried out in 384-well plates (20 l final volume) with
30 min incubation. Conditions were Hsp72 (2 M) or Hsc70
(4 M), 25 nM FITC-HLA probe, 100 mM Tris buffer, 20 mM
KCl, 6 mM MgCl2, pH 7.4.
Sequence alignment
Global sequence alignment of H. sapiens Hsp72 (HspA1A/
A29160) and Hsc70 (HspA8/ A27077) was performed using
Praline (http://www.ibi.vu.nl/programs/pralinewww/) with
manual adjustment. Figures are drawn to scale, and the
degree of residue conservancy is illustrated by color.
RESULTS
Hsp70 proteins have the capacity to both reduce and
preserve tau in cells in addition to regulating its asso-
ciation with microtubules (1, 5, 7). The reasons for
these functional differences are unclear. We speculated
that one possible reason could be the unique effects of
distinct Hsp70 variants. Since tau is a cytosolic protein,
we investigated the relationship of tau with the two
major cytosolic Hsp70 variants: Hsp72, which is in-
duced by stress (11), and Hsc70, which is constitutively
expressed (10). The effects of Hsp72 and Hsc70 over-
expression on tau stability were initially tested using a
Tet-based protein chase model in HEK cells (TauTO/
6TR). As shown in Fig. 1A, tau levels are undetectable
prior to Tet treatment and maximally induced 72 h
after Tet treatment. Once the Tet is removed, tau levels
are depleted by natural turnover processes over the
course of 72 h (Fig. 1B). Using this model, we demon-
strated that Hsc70 slowed while Hsp72 accelerated tau
clearance (Fig. 1C, D). This indicated that these two
highly similar proteins were distinctly affecting tau
turnover. We then confirmed that endogenous tau
could interact with endogenous Hsc70 and Hsp72 using
coimmunoprecipitation assays in neuronal IMR-32 cell ly-
sates analyzed by immunoblot. The neuronal cells were
first treated for 24 h with celastrol, a compound that is
known to enhance the expression of heat-shock pro-
teins, including Hsp72 (24), and destabilize microtu-
bules (25). This was done to determine whether induc-
ing Hsp72 expression might facilitate the interaction of
Hsp72 with tau. Then, 30 min prior to harvest, these
cells were also treated with the microtubule destabilizer
albendazole to release tau from microtubules, a process
that was previously found to enhance the tau/Hsc70
interaction (1). As previously reported, Hsc70 bound
more tau when microtubules were destabilized, but
celastrol treatment had no impact on Hsc70 binding to
tau (Fig. 1E). Conversely, for endogenous Hsp72 to
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bind tau in a similar manner, Hsp72 levels had to be
induced by celastrol treatment for it to bind tau in a
manner similar to Hsc70 (Fig. 1E). These data sug-
gested that relative levels of these 2 proteins could play
a critical part in deciding whether tau was to be
preserved or degraded. Our data suggested that Hsp72
was accelerating tau clearance while Hsc70 was slowing
it. Therefore, we speculated that increasing the levels of
Hsp72 could overcome any preservative effects of
Hsc70 on tau. Cells overexpressing tau were transfected
with equivalent amounts of Hsc70 along with increasing
amounts of Hsp72. Analysis of these lysates by immu-
noblot revealed that the enhanced steady-state levels of
tau by Hsc70 could indeed be negated by Hsp72
overexpression (Fig. 1F, G).
Previous work suggested that Hsp70 proteins could
promote the association of tau with microtubules (7);
however, based on our results, we speculated that
Hsc70 would affect this more potently than Hsp72.
Using colocalization analyses of GFP-tagged tubulin
and RFP-tagged tau in live cells, we found a slight
increase in tau-tubulin associations induced by Hsc70
(Fig. 2A–C). However, Hsp72 overexpression signifi-
cantly decreased the association of tau with tubulin,
further suggesting that Hsp72 promoted tau degrada-
tion (Fig. 2A–C). Western blot confirmed overexpres-
sion of both Hsp72 and Hsc70 (Fig. 2D). While these
studies supported opposing roles for these two Hsp70
variants on tau function, it still was not clear whether
Hsp72 and Hsc70 had direct effects on the ability of tau
to regulate microtubule formation. To better evaluate
this, we utilized microscopy of in vitro cell-free Xenopus
egg extracts supplemented with fluorescently labeled
tubulin and combinations of either recombinant 4R0N
tau, Hsp72, or Hsc70 alone, or 4R0N tau combined
with Hsp72 or Hsc70. Hsc70, Hsp72, and tau were all
able to promote microtubule assembly alone relative to
control, but Hsc70 and tau together appeared to dra-
matically synergize this process, producing densely
packed microtubule filaments (Fig. 3A, B). Conversely,
Hsp72 did not appear to synergize with tau: In fact,
there was a slight reduction in microtubule network
formation when Hsp72 alone was added with tau.
These findings suggested that despite their sequence
similarity, Hsp72 and Hsc70 caused distinct and even
opposing effects on tau’s function and stability. To
determine whether this was caused by differing bind-
ing locations on tau, NMR spectroscopy was used
to identify tau residues essential for Hsp72 and Hsc70
interactions. Changes in NMR signal position and
intensity in 2-dimensional 1H–15N HSQC spectra of
the 441-residue full length tau protein were observed
Figure 1. Hsp72 and Hsc70 have opposing effects on tau. A) Western blot of lysates from
HEK cells transiently transfected with tau driven by the minimal CMV promoter controlled
by the Tet response element (TauTO) or empty vector, and transiently transfected with the
Tet repressor protein (6TR). Cells were then treated with Tet and harvested at indicated
time points. B) HEK cells stably transfected with TauTO and the 6TR were treated with
indicated concentration of Tet for 24 h. After 24 h, Tet-containing medium was replaced
with medium either containing Tet (on) or without Tet (on/off), and these cells were
incubated for an additional 72 h (96 h total). Lysates were analyzed by Western blot. C)
TauTO/6TR stably transfected cells were treated with Tet for 24 h. Cells were then
transfected with Hsc70 or Hsp72 for 24 h, and tetracycline was removed. Cells were
harvested at indicated times following Tet removal. D) Quantification of tau levels in C shown as a percentage of empty
vector transfected cells (Ctrl)  sd (sd) after GAPDH normalization (n3). Open bars, dark gray bars, and light gray bars
indicate vector, Hsc70-, and Hsp72-transfected cells, respectively. E) Coimmunoprecipitation of tau from IMR-32 cell lysates
treated with DMSO alone and albendazole with DMSO, or celastrol alone and albendazole with celastrol. Then 3 M
Celastrol was applied for 24 h, followed by 20 M Albendazole treatment for 30 min. Levels of Hsp72 and Hsc70 bound to
tau were assessed. Inputs indicate whole lysates. F) Western blot of tau in lysates of HEK cells cotransfected with Hsc70 and
increasing amounts of Hsp72. G) Quantification of tau levels in F, shown as mean sd percentage of vector-transfected cells
after GAPDH normalization.
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for both Hsp70 variants in a concentration-depen-
dent manner (Fig. 4A). The observed changes were
caused by an exchange of tau between the free and the
Hsp72/Hsc70-bound state. Strong signal broadening
was particularly evident in the second and third repeats
of tau comprising the 2 hexapeptides 275VQIINK280
and 306VQIVYK311, essential for aggregation of tau into
paired helical filaments (Fig. 4B, C). These data were
consistent with previous studies belying the importance
of these motifs in chaperone-mediated autophagy
(CMA; ref. 26) and interaction with Hsc70 proteins
(27). Strikingly, much more pronounced changes in
repeats 2 and 3 were observed for Hsp72 than Hsc70
(Fig. 4B), indicating differences in the interaction
between Hsp72 and Hsc70 with tau (Fig. 4C). In
addition, weaker interactions were observed with the
residue stretches 346FKDRVQSK353 and 375KLTFRE380.
We sought to better understand the mechanism
responsible for these distinct direct effects of Hsp72
and Hsc70 on tau, and why in particular Hsp72 could
outcompete Hsc70 for tau binding. We performed
fluorescence polarization assays in which recombinant
Hsp72 and Hsc70 were incubated with both a labeled
peptide known to interact with their substrate-binding
domains (SBDs) and increasing concentrations of re-
combinant tau. Tau was able to compete with the
fluorescent mock-substrate peptide in a dose-depen-
dent manner, suggesting that tau was interacting with
the SBDs of Hsp72 and Hsc70 (Fig. 5A). While these
data showed where tau interacted with Hsp72 and
Hsc70, it did not explain why these two proteins were
causing differential effects on tau biology in cells. Using
the Praline algorithms, we found that while these two
proteins shared  80% similarity in their complete
protein sequence, their C-terminal regions had the
highest sequence variation (30%; Fig. 5B, C). There-
Figure 2. Hsc70, but not Hsp72, enhances the colocal-
ization of tau with tubulin in cells. A) Representative
2-photon fluorescent images of live HEK cells cotrans-
fected with tubulin-GFP and tau-RFP fusion constructs.
Cells transfected with vector (Ctrl) or Hsc70 showed
significant colocalization between tau and tubulin as
compared to cells transfected with Hsp72. B) Higher-
magnification imaging of areas boxed in red in A. C)
Graph demonstrating the Pearson’s colocalization coef-
ficient derived from 12 different images. Bars represent
means  sd. *P  0.05. D) Western blot of cell lysates
confirming overexpression of Flag-tagged Hsp72 and
Hsc70.
Figure 3. Hsc70, but not Hsp72, synergizes with
tau to promote microtubule assembly. A) Rep-
resentative fluorescent images of Xenopus ex-
tracts supplemented with rhodamine-labeled
tubulin and indicated combinations of recom-
binant tau, Hsp72, and Hsc70 (n10). B) Graph
demonstrating that tau, Hsp72, and Hsc70
alone could promote microtubule assembly,
but only Hsc70 combined with tau to dramati-
cally influence microtubule formation. *P 
0.05, ***P  0.001.
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fore, chimeras were constructed to blend the nucle-
otide-binding domains (NBDs), SBDs, and the most
variable C-terminal domains (CTDs) from Hsp72 and
Hsc70 (Fig. 5D) to determine which region was most
essential for the distinct tau effects. Overexpression of
these chimeras in cells revealed that constructs possess-
ing the CTD of Hsc70 preserved tau, while those
containing the CTD of Hsp72 facilitated tau clearance
(Fig. 5E, F). The NBD and SBD of both proteins
appeared to be interchangeable.
This C-terminal interaction suggested an important
role for cofactors/cochaperones of Hsp72 and Hsc70
that bind to this same region in regulating tau stability.
To test this, cells overexpressing tau and either Hsp72
or Hsc70 were transfected with siRNA targeting CHIP,
a ubiquitin ligase cochaperone known to regulate tau
turnover (5, 6, 28). Western blot of these lysates showed
that knocking down CHIP preserved tau despite over-
expression of Hsp72 or Hsc70 (Fig. 6A, B). This sug-
gested that CHIP expression was important for the
effects of Hsp72 and Hsc70 on tau in cells. To assess
whether CHIP binding to Hsp72 and Hsc70 was differ-
ent, we performed coimmunoprecipitation using anti-
Flag antibody in cells overexpressing myc-tagged CHIP,
tau, and either Flag-tagged Hsc70 or Flag-tagged
Hsp72. In cells overexpressing tau, the number of
CHIP/Hsp72 complexes was significantly greater than
the number of CHIP/Hsc70 complexes (Fig. 6C), but
surprisingly, in cells not overexpressing tau, the bind-
ing of CHIP to Hsc70 and Hsp72 was equivalent (Fig.
6D). In this way, Hsp72, but not Hsc70, in the presence
of tau and other cofactors in the cell would favor CHIP
binding to tau.
To better understand the physiological relevance of
these physical differences, we investigated the protein
levels of Hsc70 and Hsp72 in brain homogenates from
normal and AD brains. Using a dot blot, we generated
a standard curve for antibodies targeting Hsc70 and
Hsp72 to account for differences in antibody affinity
(Fig. 7A–C). We then spotted 20 g of total protein
from AD and control brains onto dot blot membranes,
probed with Hsp72 or Hsc70 antibodies, and plotted
the resulting intensities along the standard curves gen-
erated with recombinant proteins (Fig. 7A–C). Relative
quantitation of these proteins revealed that levels of
Hsc70 were 30 times greater than Hsp72, with no
difference between normal and AD brains (Fig. 7D).
Staining of mouse brain tissue produced similar results,
revealing an excess of Hsc70 relative to Hsp72 (Fig. 7E).
DISCUSSION
We have found that Hsc70 and Hsp72 have opposing
effects on tau that are driven by their relative expres-
sion levels, affinities for tau, and their C-terminal
interaction domains. The data presented here suggest
that the C-terminal dynamics of Hsc70 and Hsp72 are
essential for whether tau degradation is accelerated or
slowed. Because the CTDs of these proteins form the lid
of the substrate binding pocket and host interactions
with cochaperones that contain the TPR motif (29, 30),
Figure 4. Hsp72 binds tau with higher affinity
than Hsc70. A) Superposition of 2D 1H–15N
HSQC spectra of tau protein (50 M) in the
absence (black) and presence of an equimolar
(green) and 2-fold excess ratios of Hsp72 (or-
ange). Inset highlights the resonances of the 2
hexapeptides and their attenuation in a con-
centrationdependent manner. B, C) NMR in-
tensity ratios I/I0 (I, intensity of tau resonances
in presence of Hsp72 or Hsc70; I0, peak inten-
sities of free tau) from HSQC spectra. Signal
broadening (I/I01.0) is due to exchange of
tau between the free conformations and those
in the presence of Hsp72 or Hsc70. NMR signal
broadening of tau at increasing concentrations
of Hsp72 (B) and Hsc70 (C) (1:1 green, 2:1
orange). Domain organization of tau is shown
above (I, insert, P, proline-rich region, and R,
pseudorepeat). Asterisk corresponds to the res-
idues stretch 346FKDRVQSK353.
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we predicted that levels of cochaperones known to
interact with the C-terminal portions of Hsp72 and
Hsc70 could also have a major influence on tau triage
decisions. One such TPR-containing protein, CHIP, has
been extensively linked by our laboratory and others to
both Hsp70 proteins and tau (5, 6, 31, 32). This protein
has ubiquitin ligase activity and has been shown to
facilitate tau clearance. Here we discovered that CHIP
is able to bind to Hsc70 and Hsp72 differently when tau
is present. This suggests that there are unique struc-
tural changes to both Hsp70 variants brought on by tau
and other cochaperones that can dictate CHIP associ-
ation. Future studies will determine what these struc-
tures are and what components are needed; however,
these cellular findings point to this phenomenon as an
important component for tau triage. Perhaps this rep-
resents a mechanism for tau to maintain its own pro-
teostasis; as tau levels become overabundant and ex-
ceed the capacity of the microtubule network, tau
interacts more with Hsp72 and recruits a distinct subset
of cochaperones including CHIP to promote its self-
destruction. This would prevent its accumulation inside
neurons. However, this same recruitment of CHIP did
not occur when tau interacted with Hsc70, suggesting
that restoring or boosting the levels of Hsp72 may
supplant Hsc70 and promote tau clearance.
Interestingly, we also found that Hsp72 levels were
not induced in AD, despite the chronic stress condi-
tions that must occur during the disease course. It is
unclear why tau accumulation failed to promote more
Figure 5. C-terminal domains from Hsc70 and Hsp72 are essential for tau triage. A) FP assays with recombinant Hsp72 or Hsc70
in the presence of 1 mM ADP, the FITC-HLA (RENLRIARLY) peptide, and increasing amounts of recombinant tau were carried
out in 384-well plates (20 l final volume) with 30 min incubation. Results are the average of experiments performed in
triplicate; error bars represent sem. B, C) Sequence alignment showing 29% sequence variability in the C termini of Hsp72 and
Hsc70. D) Schematic of Hsc70/Hsp72 chimera design. E) Western blot of lysates from HeLa cells stably expressing tau and
transfected with Flag-tagged Hsc70/Hsp72 chimeras. F) Quantification of tau levels in D shown as mean  sd percentage of
vector-transfected cells (Ctrl) after GAPDH normalization (n3).
Figure 6. Tau influences the composition of Hsp70/CHIP complexes, affecting its own triage. A) Western blots of HeLa cells
that were transfected with Hsp72, Hsc70, and siRNA for CHIP. B) Quantification of tau levels in A, shown as mean  sd ratio
to actin derived from 3 repeated experiments. C, D) Western blot of samples coimmunoprecipitated with anti-Flag antibody with
(C) or without (D) tau overexpression shows that tau selectively increases the association of Hsp72 with CHIP.
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robust expression of Hsp72 in contrast to what has been
reported for other neurodegenerative diseases brought
on by protein misfolding and accumulation (11, 33). It
is possible that Hsp72 levels are elevated early in the
disease process, but then attenuate over time back to
baseline levels due to the chronic proteotoxic stress. We
would predict that even a small increase in Hsp72 could
counterbalance tau burden by subverting the preserva-
tive effects of Hsc70 due to the enhanced affinity of
Hsp72 for Hsc70, but not even slight increases were
observed in human AD or tau transgenic mouse brain
tissue. This could be indicative of the failing heat shock
response that occurs in general with age (34, 35). Thus,
selective enhancement of Hsp72 levels with small mol-
ecules or gene therapies could favor an environment
that removes excess tau.
Using NMR spectroscopy, we identified the binding
motifs for a chaperone on tau. As expected, both Hsc70
and Hsp72 shared binding sites within the microtubule-
binding domains of tau. In particular, consistent with
previous studies using traditional mutagenesis, the
275VQIINK280 and 306VQIVYK311 hexapeptide motifs
were found to be critical for binding these chaperones
to tau (26, 27). These motifs are particularly important
for tau in that they are necessary for tau aggregation
(36, 37) and triage toward an inefficient CMA pathway
(26). These proamyloid motifs reside in most proteins
(38) and may serve as beacons for chaperones (39, 40).
Thus, as tau disengages from microtubules, these mo-
tifs are exposed, recruiting available chaperones. It is at
this point that the balance between Hsp72 and Hsc70
may be most critical. Hsc70 is necessary for CMA in that
it facilitates the triage of certain proteins toward Lamp2a, a
lysosomal membrane protein for CMA substrates (41);
however, Hsp72 does not have a similar function. While
facilitating CMA would at first seem beneficial in pro-
moting tau clearance, tau actually is anchored to the
lysosomal membrane following its triage to Lamp2a,
whereby it is then proteolytically cleaved and primed
for aggregation (26).
Using NMR, we were also able to identify some additional
consensus sites 346FKDRVQSK353 and 375KLTFRE380 that
were previously unidentified. Most intriguingly, the
lysine at 353 is part of the known KXGS consensus
sequence for the microtubule affinity regulating kinase
2 (MARK2). We previously demonstrated that CHIP is
less prone to interact with tau when it is phosphorylated
at MARK2 consensus sites (42–44). MARK2 promotes
the release of tau from microtubules (45) while also
altering tau sorting within neurons (46). Since tau
phosphorylated at these sites is protected from CHIP
interaction, it suggests that this is a strategy adopted by
the neuron to preserve tau during plasticity to conserve
energy. We speculate that to promote plasticity, tau
must detach from microtubules, but without a post-
translational modification of some sort, a CHIP/Hsp72
Figure 7. Hsc70 levels are much higher than Hsp72 in human brain. A, B) Recombinant Hsc70 (A) and Hsp72 (B) were spotted
onto nitrocellulose at indicated concentrations alongside 20 g of total protein from normal and AD brain lysates. Ponceau S
was performed, followed by blocking and immunoblot with anti-Hsc70 or anti-Hsp72 antibodies. C) Semilog linear regression
analysis was performed using the values of the recombinant protein to normalize for difference in antibody affinity. D)
Abundance of Hsc70 (dark gray bars) and Hsp72 (light gray bars) immunoreactivity in lysates from normal and AD human brain
(n3/group) normalized to the standard curve composed of recombinant Hsc70 and Hsp72, respectively, in A and B. E)
Representative images of immunostaining of mouse brain (n4) with Hsc70 and Hsp72 antibodies.
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complex would quickly bind and promote tau clear-
ance, a step that would require new tau protein to be
synthesized after every axonal plastic event. By promot-
ing phosphorylation of tau near the CHIP/Hsp72
binding sites, the neuron can preserve tau and conserve
energy by allowing tau recycling: But this comes with a
price: Phosphorylation of tau destabilizes the axonal
diffusion barrier that prevents tau localization to the
soma and dendrites (46), the subcellular location
where tau pathology is typically found in AD and other
tauopathies. Therefore, while preventing CHIP/Hsp72
binding through MARK2 phosphorylation may be en-
ergetically favorable for the neuron, it allows tau to
move into the somatodendritic compartment where it
is known to accumulate and become toxic. A delicate
balance is required to meet energy demands while also
preventing proteotoxicity. Expression levels of Hsp70
variants, tau phosphorylation, microtubule integrity,
and neuronal trafficking all must be managed to pre-
vent tau from accumulating to the point of being
neurotoxic. If any of these processes are altered, the
toxic sequelae of tau can be accelerated. Thus, inter-
ventions aimed at any of these pathways could be
effective therapeutics for managing tauopathies.
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